The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial.
A. M. G. Ali
No relevant relationships to disclose
E. Provenzano
No relevant relationships to disclose
J. Abraham
No relevant relationships to disclose
J. M. Bartlett
No relevant relationships to disclose
C. J. Poole
Honoraria - Pfizer
Research Funding - Pfizer
L. Hiller
No relevant relationships to disclose
J. Dunn
No relevant relationships to disclose
C. Twelves
No relevant relationships to disclose
H. M. Earl
No relevant relationships to disclose
C. Caldas
No relevant relationships to disclose
P. Pharoah
No relevant relationships to disclose